Haemangiosarcoma (HSA) has an aggressive biological behaviour and carries a poor prognosis, with less than 10% of treated dogs surviving longer than 1 year. In this retrospective study a varied metronomic chemotherapy (MC) regimen preceded by adjuvant doxorubicin-based maximum-tolerated dose chemotherapy (MTDC) was compared with MTDC, in terms of efficacy [time to metastasis, (TTM) and survival time (ST)] and safety in dogs with biologically aggressive HSA. Dogs were eligible if they had no metastasis after MTDC and received either no further chemotherapy or MC maintenance. Twelve dogs received MTDC, and 10 received MC thereafter. Median TTM and ST were significantly longer for dogs receiving MTDC-MC (not reached versus 150 days, P = 0.028; and not reached versus 168 days, P = 0.030, respectively). Treatment was well tolerated. MTDC followed by MC is safe and suggests improved TTM and ST in dogs with surgically removed, biologically aggressive HSA that are treated in the microscopic setting.

Diffuse large B‐cell lymphoma (DLBCL) is the most common haematopoietic tumour in dogs and recognized as clinical model for its human counterpart. Recently, neutrophil‐to‐lymphocyte (NLR) and lymphocyte‐to‐monocyte (LMR) ratios have been shown to predict time‐to‐progression (TTP) and lymphoma‐specific survival (LSS) in dogs with DLBCL treated with CHOP‐based chemotherapy. We retrospectively evaluated in 59 dogs diagnosed with DLBCL the prognostic value of haematological parameters and derived ratios: NLR, LMR, platelet‐to‐lymphocyte (PLR) and platelet‐to‐neutrophil (PNR) ratios for TTP, LSS and associated secondary end‐points (time‐to‐progression‐rate [TTPR] and lymphoma‐specific survival‐rate [LSSR]) as rates at 180 and 365 days. PNR is an independent prognostic marker (p ≤ .001) for TTPR/180 and 365 days, dogs with a PNR above 0.032 were more likely to progress before 180 days (sensitivity 46.5%, specificity 87.5%, p = .004). On univariate analysis, NLR showed a prognostic significance for LSSR/180 (p = .006) and LSSR/365 (p = .009). A baseline NLR value below 7.45 was positively associated with survival at 180 days (sensitivity 52%, specificity 85.3%, p = .025). The presence of substage b, was associated with early progression and decreased survival at 180 days (p = .031). Anaemia significantly reduced LSSR at 365 days (p = .028). This is the first study evaluating PLR and PNR in canine DLBCL and demonstrates that PNR could be a predictor of early lymphoma progression. Since peripheral blood cell composition can be affected by several non‐oncological causes, the development of larger multicenter studies with homogeneous inclusion criteria could help to better determine the true predictive values of blood cell ratios in dogs' DLBCL treated with CHOP chemotherapy.

There are an increasing number of reports describing the development of hyperkalaemia in healthy veterinary patients during general anaesthesia. While the majority of cases are dogs, it has also been described in large non-domestic cats under general anaesthesia. To the authors’ knowledge, there are no reported cases of acute hyperkalaemia in healthy domestic cats associated with anaesthesia. This case report describes the development of hyperkalaemia in a nine-year-old domestic short-haired cat, anaesthetised for fracture repair. Hyperkalaemia (8.0 mmol/l) was recognised due to the sudden development of bradycardia, spiked T waves, decreased amplitude of P waves, progressing to atrial standstill on the ECG. Initial treatment was with calcium gluconate, insulin and glucose, which resolved the problem, but the hyperkalaemia recurred during recovery from anaesthesia, necessitating further treatment. Possible causes of the hyperkalaemia are discussed.

Paired box gene 5 (Pax5) is a widely used B-cell marker for human and canine non-Hodgkin's lymphoma (nHL); however, in the literature there is only one case report using Pax5 in a cat B-cell lymphoma. The purposes of this study were to investigate the expression and detection of B-cell specific activator protein (BSAP) using a monoclonal anti-Pax5 antibody in feline nHL (FnHL) tissue samples to evaluate its diagnostic relevance as a B-cell marker. A total of 45 FnHL samples in 45 cats were evaluated. B-cell lymphoma was the most common immunophenotype (51.1%) for all the samples and T-cell the most common immunophenotype (64.3%) for the gastrointestinal (GI) form. Pax5 stained 82.6% of all B-cell lymphomas and no expression was found in any of the T-cell lymphomas. Anti-Pax5 antibody staining in FnHL is similar to that reported in human and canine counterparts and may offer an excellent B-cell marker in cats.

Lymphoma is the most common haematological malignancy in dogs and its aetiology is largely unknown. The presence of canine vector‐borne agents (CVBD) in lymphoma tissues has been described and its causative effects questioned. We intended to evaluate the presence and extent of Leishmania infantum, Ehrlichia canis, Anaplasma phagocytophilum and Bartonella henselae infection in dogs with lymphoma. Sixty‐one dogs, living in the Lisbon metropolitan area, with a diagnosis of lymphoma were enrolled. Immunofluorescence assays were used to detect serum IgG's. The presence of DNA from CVBD agents in tumour tissue was assessed by PCR. All dogs tested negative for B. henselae, A. phagocytophilum and E. canis by both serology and PCR. Regarding L. infantum, 8.2% (n = 5) of the dogs had a positive serologic result. L. infantum DNA was detected in two samples of diffuse large B‐cell lymphoma (DLBCL). These results show an increased, but not significant, seropositivity (8.2% vs 7.9%) and molecular detection (3.3% vs 1.2%) for L. infantum in dogs with lymphoma, when compared to the reported canine population in the same geographical area. We could not identify an association between lymphoma and E. canis, A. phagocytophilum, B. henselae or Leishmania infantum infection in the studied population. Nevertheless, further studies, following dogs trough their CVBD disease evolution, are worthwhile and may help clarify a possible role of CVBD agents in lymphomagenesis.

The beneficial effects of performing regional anaesthesia techniques as part of a pre‐emptive analgesic strategy are to improve perioperative analgesia and reduce opioid and general anaesthetic drug requirements. In prey species, an early recovery of voluntary motor function, especially after a regional anaesthesia, is essential for the animal's health and welfare. To reduce motor paralysis, a low volume and concentration of local anaesthetic should be administered close to the targeted nerve. This is the first report of an ultrasound (14 MHz linear probe)‐ and nerve stimulation (0.2 mA; 0.3 second; 2 Hz)‐guided saphenous and sciatic nerve blocks using bupivacaine (0.125%; 0.2 mL/kg per nerve) in a rabbit. Drug consumption, physiological response to surgery and postoperative pain scoring were used to determine block success. The ultrasound‐ and nerve stimulation‐guided sciatic and saphenous nerve blocks could be recommended as part of multimodal pain management in rabbits undergoing appropriate pelvic limb orthopaedic surgeries.

No abstract

Ultrasound-guided (US-guided) loco-regional anesthesia can provide significant analgesia and anesthetic-sparing effects when used in rabbits. The aims of this study were to investigate the thoraco-lumbar anatomy of the rabbits, particularly the quadratus lumborum (QL) muscle, to design an appropriate US-guided quadratus lumborum block (QLB) specific for rabbits, and to define the most adequate volume of injectate required to consistently cover the ventral branches of T11 to L3 without affecting the pelvic limb innervation (L4, L5 and L6). Sixteen adult rabbit cadavers were included in the study. After randomization, four different volumes of injectate (0.1 mL/kg, 0.2 mL/kg, 0.3 mL/kg and 0.4 mL/kg) were tested, with these volumes additionally randomized to two sites of injection (right or left QL fascia). An ultrasound-guided QLB was performed with a solution of lidocaine, iodinated contrast and tissue dye (in a proportion of 3:1:1 volume, respectively), with subsequent computed tomography (CT) and anatomical dissection, to evaluate the spread of the injectate. In all but one case, the US-guided QLB performed with a dorsolateral approach using 0.3 mL/kg was adequate, while a dose of 0.4 mL/kg consistently reached the targeted nerves but also extended to L4 and caudally. This may suggest that an injectate volume of 0.3 mL/kg may be the most appropriate to produce adequate spread while not affecting pelvic limb innervation.